Literature DB >> 6692424

Liposomes as drug carriers in cancer therapy.

J N Weinstein.   

Abstract

Liposomes, microscopic particles composed of lipid bilayer membranes, can carry water-soluble drugs in their aqueous compartments and lipid soluble drugs in their bilayers. Over the last 10 years, they have been studied more intensively than any other type of drug carrier. The first impulse, as with other pharmaceuticals, has been to inject them iv. However, since they do not leave the vascular system readily except in the sinusoids of liver and spleen, many of the projected applications to nonhematogenous cancers are unlikely to succeed. Nonetheless, the last few years have brought a great increase in sophistication with respect to the physical chemistry, biochemistry, and pharmacology of liposomes. Routes other than the vascular are being explored, and iv injection is being exploited for access to targets within the vascular space. The most likely clinical applications to be successful soon are in parasitology and immunology; practical applications in oncology are distinctly possible, but still speculative.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692424

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  14 in total

1.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.

Authors:  C P Leamon; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  Uptake of antibody directed cytotoxic liposomes by CD3 on human T cells.

Authors:  A G Gray; J Morgan; D C Linch; E R Huehns
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 3.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 4.  Carrier erythrocytes. Clinical pharmacokinetic considerations.

Authors:  M Tonetti; A De Flora
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

5.  The antitumor effects of adriamycin entrapped in liposomes on lymph node metastases.

Authors:  H Konno; T Tadakuma; K Kumai; T Takahashi; K Ishibiki; O Abe; S Sakaguchi
Journal:  Jpn J Surg       Date:  1990-07

6.  Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.

Authors:  P Zanovello; A Rosato; V Bronte; S Mandruzzato; V Cerundolo; D Collavo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Antiproliferative effects of free and liposome-encapsulated retinoic acid in a squamous carcinoma model: monolayer cells and multicellular tumor spheroids.

Authors:  P G Sacks; V Oke; K Mehta
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 8.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report.

Authors:  K Lee; K Chan; W T Leung; N W Leung; S Ho; M Chan; C C Lau; M Tao; W Y Lau; W Shiu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

10.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.